Related by context. All words. (Click for frequent words.) 65 NMIBC 64 cancerous enlargement 64 pancreatic adenocarcinoma 63 BCG refractory 63 metastatic renal cell carcinoma 63 neoadjuvant therapy 63 chemoradiotherapy 63 Amrubicin 62 stage IIIB 62 pheochromocytoma 62 neoadjuvant 61 papillary renal cell carcinoma 61 adjuvant radiation 61 soft tissue sarcomas 61 HRPC 61 metastatic colorectal 61 Irinotecan 61 seminoma 61 bone metastasis 61 radical nephrectomy 61 metastatic renal 61 Proxinium TM 61 TACE 61 BRIM2 61 recurrent NSCLC 60 transplantation HCT 60 malignant pleural mesothelioma 60 recurrent glioblastoma multiforme 60 hepatic metastases 60 HER2 positive metastatic breast 60 Apaziquone 60 medically inoperable 60 urothelial cancer 60 carboplatin paclitaxel 60 renal tumors 60 intravesical therapy 60 LHRH receptor positive 60 metastatic bladder 60 resectable 60 NSCLC 60 HNSCC 60 castrate resistant prostate cancer 60 lymphadenectomy 60 chemoradiation 60 urothelial carcinoma 60 allogeneic hematopoietic stem cell 60 metastatic hormone refractory 60 fallopian tube carcinoma 60 prostate cancer CaP 60 locoregional recurrence 60 androgen deprivation 60 pain palliation 60 chemoembolization 60 vinorelbine 60 vinca alkaloid 60 hypercalcemia 59 leiomyomas 59 gemcitabine Gemzar ® 59 metastatic RCC 59 IV NSCLC 59 cystectomy 59 Surgical resection 59 allogeneic stem cell 59 mg/m2 dose 59 metastatic castrate resistant 59 B Cell Lymphoma 59 CHOP chemotherapy 59 unresectable liver cancer 59 colorectal carcinoma 59 metastatic relapsed 59 unresectable 59 chemoresistant 59 underwent surgical resection 59 superficial bladder cancer 59 undergone radical prostatectomy 59 GnRH agonists 59 Advanced Renal Cell 59 nephrectomy 59 Vicinium TM 59 nonmetastatic 59 peritoneal carcinomatosis 59 advanced metastatic prostate 59 Doxil ® 59 Metastatic 59 thromboembolic events 59 neoadjuvant chemotherapy 59 situ CIS 59 basal cell carcinoma BCC 59 biochemical recurrence 59 Mitomycin C 59 Octreolin 59 BR.# 59 mRCC 59 differentiated thyroid 59 breast carcinoma 59 cytoreduction 58 transplantation HSCT 58 squamous cell carcinoma SCC 58 sorafenib Nexavar 58 SCCHN 58 mycophenolate mofetil 58 metastatic malignant melanoma 58 histone deacetylase HDAC inhibitor 58 cancer mCRC 58 leukemia AML 58 platinum refractory 58 radiotherapy RT 58 urothelial bladder cancer 58 EGFR expressing 58 papillary thyroid carcinoma 58 metastatic GIST 58 cutaneous T cell 58 Group RTOG 58 radical cystectomy 58 advanced hepatocellular carcinoma 58 MGd 58 Cell Lung Cancer 58 histone deacetylase inhibitor 58 stage IIIb IV 58 transitional cell carcinoma 58 familial amyloidotic polyneuropathy FAP 58 chronic GVHD 58 neoplastic 58 relapsed ovarian cancer 58 multicentric 58 metastatic gastric 58 Lenalidomide 58 recurrent metastatic 58 lung pancreatic 58 cell lymphoma CTCL 58 hepatocellular carcinoma 58 depsipeptide 58 bone metastases 58 gastrointestinal stromal tumors 58 Mantle Cell Lymphoma 58 gastric cancers 58 ErbB2 positive 58 ELACYT 58 peritumoral brain edema 58 adenomatous 58 Bezielle 58 metastatic pancreatic 58 prostate cancer CRPC 58 ischemic cardiomyopathy 57 prospective multicenter 57 pegylated liposomal doxorubicin 57 skeletal metastases 57 gemcitabine Gemzar 57 Gemcitabine 57 pouchitis 57 apaziquone 57 clinically localized prostate 57 histologies 57 metastatic breast 57 histologic subtype 57 relapsed multiple myeloma 57 OPAXIO 57 underwent resection 57 unstable angina UA 57 relapsed MM 57 paclitaxel carboplatin 57 Atypical Hemolytic Uremic Syndrome 57 gadolinium enhanced 57 external beam radiotherapy 57 fluoropyrimidine 57 Papillary 57 Neoadjuvant 57 erlotinib Tarceva ® 57 nephron sparing surgery 57 immunohistochemical staining 57 Relapsed Refractory 57 ZACTIMA 57 adenocarcinomas 57 retroperitoneal 57 EGFR HER2 57 localized renal 57 colorectal liver metastases 57 intravesical instillation 57 cytotoxic chemotherapy 57 PCa 57 hepatocellular cancer 57 prostate carcinoma 57 epithelial ovarian 57 posaconazole 57 metastatic bone 57 RTOG 57 secondary hyperparathyroidism 57 neuroendocrine cancers 57 refractory prostate cancer 57 Radioimmunotherapy 57 pancreatic carcinoma 57 5FU 57 CTAP# Capsules 57 colon carcinoma 57 urothelial 57 adecatumumab 57 carcinoids 57 cytoreductive surgery 57 adjuvant radiotherapy 57 atypical Hemolytic Uremic Syndrome 57 hematologic toxicity 57 Tamibarotene 57 imetelstat 57 doublet chemotherapy 57 malignant neoplasm 57 liver transplant recipients 57 metastatic prostate cancer 57 OncoVEX GM CSF 57 essential thrombocythemia ET 57 nab paclitaxel 57 hepatocellular carcinoma HCC 57 locoregional 57 Diabetic Macular Edema 57 Gefitinib 57 recurrent DVT 57 FOLFOX6 57 chemotherapeutic regimens 57 Pemetrexed 57 neuroendocrine tumors 57 CYT# potent vascular disrupting 57 intravesical 57 BEACOPP 57 Epidermal Growth Factor Receptor 57 medullary thyroid cancer 57 metastatic liver 57 preoperative chemotherapy 57 FASLODEX 57 Androgen Deprivation Therapy 57 Carcinoma 57 FOLPI 57 radiolabeled TM# 57 HGPIN 57 osteosarcomas 57 CsA 57 androgen independent 57 CLL SLL 57 GISTs 57 patients undergoing CABG 57 carcinomas 57 multiple myeloma MM 56 Renal cell carcinoma 56 Anthracycline 56 ixabepilone 56 carcinoma 56 mycosis fungoides 56 decitabine 56 gastric adenocarcinoma 56 Radical prostatectomy 56 cutaneous T 56 Radiation Therapy SIRT 56 F FDG PET 56 oral clodronate 56 Gemzar ® 56 LHRH agonists 56 relapsing multiple sclerosis 56 Follicular Lymphoma 56 concurrent chemoradiation 56 serous ovarian cancer 56 brain metastases 56 cervical carcinoma 56 intravesical infusion therapy 56 unresectable tumors 56 trabectedin 56 Peginterferon alfa 2b 56 FOLFOX4 56 gemcitabine chemotherapy 56 Critical Limb Ischemia CLI 56 ThermoDox R 56 prostate cancer HRPC 56 recurrent GBM 56 phase IIb clinical 56 biologic therapy 56 histologically confirmed 56 TEMODAL 56 hepatitis C HCV 56 cinacalcet 56 grade cervical intraepithelial 56 symptomatic BPH 56 HBeAg negative 56 recurrent malignant glioma 56 5-FU/LV 56 advanced metastatic renal 56 platelet inhibitor 56 BCG refractory carcinoma 56 epithelial ovarian cancer 56 curative resection 56 diagnosed glioblastoma multiforme 56 plus gemcitabine 56 Hodgkin lymphoma HL 56 Anaplastic 56 pulmonary metastases 56 biochemical relapse 56 pancreatic gastric 56 fallopian tube cancers 56 cisplatin gemcitabine 56 Erlotinib 56 bleomycin 56 Ranolazine 56 follicular lymphomas 56 thymoma 56 KRAS status 56 liposomal doxorubicin 56 metastatic HRPC 56 lymphoma CTCL 56 paragangliomas 56 mCRC patients 56 metachronous 56 Sezary syndrome 56 kidney urologic 56 rFVIIa 56 veltuzumab 56 NSABP B 56 Myelofibrosis 56 gefitinib Iressa 56 pamidronate 56 advanced unresectable 56 gastroduodenal 56 malignant lymphoma 56 Estrogen Receptor 56 bevacizumab Avastin 56 gastroesophageal junction 56 non metastatic resectable 56 palliative radiotherapy 56 Cell Lymphoma 56 intestinal metaplasia 56 neoadjuvant treatment 56 unresectable stage 56 Perifosine 56 heavily pretreated 56 pancreatic islet cell 56 temsirolimus 56 Progenitor Cells 56 liver resection 56 sunitinib malate 56 prostate adenocarcinoma 56 metastatic 56 metastatic prostate 56 radiochemotherapy 56 dose cytarabine 56 pCR 56 Prolongs Survival 56 ABCB1 56 PEGylated interferon beta 1a 56 indolent NHL 56 renal cell carcinoma 56 prostate pancreatic 56 endocrine therapies 56 hypoparathyroidism 56 ABVD 56 hormone refractory metastatic prostate 56 AQ4N 56 ST Segment Elevation 56 Adenocarcinoma 56 Hormone Refractory Prostate Cancer 56 resected 56 glycoprotein IIb IIIa inhibitors 56 mTOR inhibitors 56 benign prostatic hypertrophy BPH 56 hyperplastic 56 immunohistochemical 56 anthracyclines 56 Benign Prostatic Hyperplasia BPH 56 relapsed refractory multiple myeloma 56 prognostic indicator 56 Patients Treated With 56 relapsing remitting MS RRMS 56 docetaxel Taxotere ® 56 occlusive disease 56 comparator arm 56 azacitidine 56 Medullary thyroid cancer 56 metastatic neuroendocrine tumors 56 XGEVA 56 malignant neoplasms 56 Unresectable 56 breast pancreatic 56 estramustine 56 antibody MAb 56 immunomodulatory therapy 56 cytoreductive nephrectomy 56 Glioblastoma Multiforme 55 anastrazole 55 Metastatic Prostate Cancer 55 trastuzumab Herceptin R 55 diagnosed multiple myeloma 55 hormone refractory prostate cancer 55 mutated KRAS 55 Glioma 55 IL# PE#QQR 55 melphalan prednisone 55 malignant fibrous histiocytoma 55 nonischemic 55 Thrombolysis 55 proliferative diabetic retinopathy 55 Nilotinib 55 benign neoplasms 55 adjuvant therapy 55 Etoposide 55 osteoblastic 55 CIMZIA TM certolizumab pegol 55 Renal Cell Carcinoma 55 pancreatic colon 55 acute promyelocytic leukemia APL 55 resistant ovarian cancer 55 Blinatumomab 55 tumors GIST 55 EFAPROXYN 55 Hepatocellular Carcinoma 55 haematologic 55 pT2 55 Genasense ® 55 Metastatic Colorectal Cancer 55 tumor histology 55 Ischemic 55 Degarelix 55 Pralatrexate 55 PANVAC VF 55 lenalidomide Revlimid R 55 acute myeloid 55 lymphocytosis 55 drug zotarolimus 55 myocardial ischemia 55 Percutaneous Coronary Intervention 55 intravenous bisphosphonates 55 orthotopic 55 anthracycline taxane 55 Allogeneic 55 vertebral compression fractures 55 advanced adenomas 55 heavily pretreated patients 55 Natalizumab 55 cervical lymph nodes 55 ovarian lung 55 Ibritumomab Tiuxetan 55 Phase #b/#a clinical 55 cutaneous squamous cell carcinoma 55 T1c 55 invasive aspergillosis 55 myelodysplastic syndrome MDS 55 pegylated interferon alfa 2b 55 Navelbine 55 investigational immunotherapy 55 mitomycin C 55 nodal metastases 55 recurrent ovarian cancer 55 malignant ascites 55 debulking surgery 55 IRX 2 55 xenograft models 55 Adjuvant chemotherapy 55 catheter angiography 55 dasatinib Sprycel ® 55 operable breast cancer 55 common hematologic malignancy 55 radical prostatectomy RP 55 colorectal adenoma 55 ALCL 55 squamous histology 55 axillary lymph nodes 55 refractory multiple myeloma 55 topotecan 55 Soft Tissue Sarcoma 55 intraperitoneal chemotherapy 55 ACTEMRA TM 55 Zoledronic acid 55 pituitary adenomas 55 antiangiogenic therapy 55 Castration Resistant Prostate Cancer 55 complement inhibitor eculizumab 55 lung metastases 55 EGFr 55 receptor tyrosine kinase inhibitor 55 syngeneic 55 smoldering multiple myeloma 55 metastatic castration resistant 55 epithelioid 55 PSMA ADC 55 LHRH agonist 55 SHPT 55 ALA PDT 55 recurrent squamous cell carcinoma 55 riociguat 55 Renal Cell Carcinoma RCC 55 invasive coronary angiography 55 B CLL 55 Acute Coronary Syndromes ACS 55 grade gliomas 55 APPRAISE 55 alkylating agent 55 BAY #-# 55 TAXOTERE R 55 subependymal giant cell 55 BCIRG 55 Bevacizumab 55 sorafenib tablets 55 non squamous NSCLC 55 locoregional disease 55 subtrochanteric 55 hENT1 55 hepatorenal syndrome 55 Patients Treated 55 recurrent glioma 55 cisplatin chemotherapy 55 IMiDs ® compound 55 Toxicities 55 tanespimycin 55 Allovectin 7 ® 55 non squamous 55 vorinostat 55 acute GvHD 55 biologic DMARD 55 epirubicin 55 complete remissions 55 mediastinal 55 PNP inhibitor 55 evaluable patients 55 extracranial 55 STRIDE PD 55 EBRT 55 bronchogenic carcinoma 55 monoclonal anti 55 FDG PET 55 Pivotal Trial 55 Capecitabine 55 stable angina 55 infantile onset 55 Taxotere ® 55 remission induction 55 noninfectious uveitis 55 alfa 2a 55 epithelial tumors 55 recurrent ovarian 55 Adjuvant Chemotherapy 55 pan HDAC inhibitor 55 myocardial perfusion imaging 55 DOXIL 55 Tavocept 55 intratumoral injection 55 Hsp# Inhibitor 55 Aflibercept 55 Metastatic breast cancer 55 Stereotactic Body Radiation Therapy 55 surgically resectable 55 MAGE A3 ASCI 55 paclitaxel poliglumex 55 thyroid nodules 55 IMC A# 55 erythropoietic 55 mitoxantrone 55 squamous 55 Neulasta ® 55 histological subtype 55 visilizumab 55 distant metastasis 55 metastatic CRC 55 prostate cancer PCa 55 endometrial hyperplasia 55 iniparib BSI 55 ALND 55 CTCL 55 relapsed leukemia 55 neoplastic cells 55 carcinoid tumors 55 neoplasms 55 colorectal lung 55 unresectable locally advanced 55 Velcade bortezomib 55 adjuvant therapies 55 TRISENOX 55 oral deforolimus 55 Taxotere R 55 taxane therapy 55 MACCE 55 neoplastic lesions 55 HER2 positive 54 Metastatic Melanoma 54 TheraSphere 54 clinicopathological 54 CIMZIA ™ 54 castrate resistant 54 HER2 negative 54 zoledronic acid 54 pelvic lymphadenectomy 54 T1a 54 cytologically confirmed 54 antibody MT# 54 CINTREDEKIN BESUDOTOX 54 antiproliferative effects 54 panobinostat 54 paroxysmal nocturnal hemoglobinuria PNH 54 metastatic disease 54 carcinoma HCC 54 extranodal 54 essential thrombocythemia 54 ovarian carcinoma 54 oncological indications 54 nonmelanoma skin cancers 54 interferon gamma 1b 54 FDG-PET/CT 54 dacarbazine 54 biliary tract cancer 54 cisplatin 54 antitumor activity 54 XYOTAX TM 54 Idiopathic Pulmonary Fibrosis 54 nonalcoholic steatohepatitis NASH 54 SSc 54 INSPIRE Trial Phase III 54 bladder cancers 54 sarcomatoid 54 underwent radical prostatectomy 54 chlorambucil 54 Alemtuzumab 54 metastatic lung cancer 54 PD LID 54 dose melphalan 54 GEM OS1 54 retinal vein occlusion 54 ximelagatran 54 azacytidine 54 situ LCIS 54 hematological diseases 54 EGFR mutation positive 54 Adjuvant Treatment 54 Chronic lymphocytic leukemia 54 adrenalectomy 54 metastatic renal cell 54 cintredekin besudotox 54 liver metastases 54 sunitinib Sutent 54 busulfan 54 Li Fraumeni Syndrome 54 evaluable 54 pT3 54 histologic 54 Factor VIIa 54 metastatic colorectal carcinoma 54 somatostatin analog 54 tumor resection 54 daunorubicin 54 palifermin 54 PAOD 54 Randomized Phase 54 FOLFOX 54 gastrointestinal stromal tumor 54 calcineurin inhibitor 54 severe oral mucositis 54 Interferon alfa 54 papillary 54 chemoradiation therapy 54 calcium phosphate binder 54 Bronchiectasis 54 hormone refractory 54 Phase III randomized controlled 54 Neovascular AMD 54 paraganglioma 54 Bortezomib 54 INCB# [003] 54 completely resected 54 Fludarabine 54 demonstrated antitumor activity 54 anti EGFR antibody 54 metastatic colorectal cancer 54 allogeneic 54 antitumor effect 54 recurrent glioblastoma 54 Mitoxantrone 54 Temsirolimus 54 LEUKINE 54 Fludara 54 Cutaneous T 54 Vidaza azacitidine 54 vandetanib 54 Gleevec resistant 54 Glufosfamide 54 acadesine 54 myelosuppression 54 Diabetic nephropathy 54 alcoholic fatty liver 54 Carcinoid tumors 54 lung cancer NSCLC 54 adrenocortical cancer 54 elacytarabine 54 II Clinical Trial 54 transthyretin amyloidosis 54 cell lung cancer 54 DLBCL 54 romidepsin 54 metastatic malignant 54 prostate carcinomas 54 doxorubicin cyclophosphamide 54 Oral Fingolimod 54 malignant cancerous 54 bevacizumab Avastin ® 54 evaluating tivozanib 54 multivessel disease 54 GW# [003] 54 surgical debulking 54 aromatase inhibitors AIs 54 postoperative chemotherapy 54 AA Amyloidosis 54 hepatocellular carcinomas 54 relapsed SCLC 54 recurrent prostate cancer 54 unstable angina pectoris 54 adriamycin 54 TTF Therapy 54 Uricase PEG 54 leiomyosarcoma 54 lymphadenopathy 54 Myelodysplastic Syndrome 54 Vandetanib 54 Antiviral Therapy 54 lupus nephritis 54 overlapping toxicities 54 investigational monoclonal antibody 54 Etanercept 54 CIMZIA TM 54 Chronic Lymphocytic Leukemia CLL 54 non valvular atrial 54 CYPHER Stent 54 prospective multicenter study 54 thetreatment 54 dasatinib Sprycel 54 TORISEL 54 ADHF 54 cholangiocarcinoma 54 CTEPH 54 active comparator 54 herpetic keratitis 54 supratentorial 54 synovial tissue 54 Chemoradiation 54 lenalidomide dexamethasone 54 Xanafide 54 Fibrin Pad 54 cisplatin resistant 54 bladder carcinoma 54 Rheumatoid Arthritis Patients 54 FUSILEV enhances 54 CaP 54 Adenomas 54 Ozarelix 54 Invasive Breast Cancer 54 Protelos 54 Torisel 54 trans retinoic acid 54 trastuzumab Herceptin ® 54 pancreatic prostate 54 assessing T DM1 54 HuMax EGFr 54 LUX Lung 54 docetaxel Taxotere R 54 invasive lobular carcinoma 54 HER2 overexpression 54 Antitumor Activity 54 prokinetic agent 54 resistant hormone refractory 54 vertebral fracture 54 multicenter study 54 clinico pathological 54 Tanespimycin 54 octreotide LAR 54 gemcitabine 54 relapsed Hodgkin lymphoma 54 Randomized Study 54 pomalidomide 54 GvHD 54 esophageal carcinoma 54 osteoporotic 54 intralesional 54 Neovascular Age Related Macular 54 farletuzumab 54 autologous hematopoietic stem cell 54 novel VDA molecule 54 haematological malignancies 54 astrocytoma 54 interferon ribavirin 54 Bladder Cancer 54 liposomal amphotericin B 54 microsphere therapy 54 Nimotuzumab 54 Flu Cy 54 HSCT 54 targeted radiotherapeutic 54 Myelodysplastic syndromes MDS 54 solid organ transplantation 54 MabCampath 54 HuMax CD4 54 Solid Tumors 54 Chronic Heart Failure 54 autologous cellular immunotherapy 54 Hurthle cell 54 tumor recurrence 54 leiomyoma 54 immunotherapeutic agent 54 basal cell skin 54 TYKERB 54 tumor lysis syndrome 54 Ceplene/IL-2 54 allogeneic SCT 54 lung carcinomas 54 RAPAFLO R 54 acute coronary syndromes ACS 54 polycythemia vera essential thrombocythemia 54 thromboembolic 54 refractory NSCLC 54 luteinizing hormone releasing 54 malignant pleural mesothelioma MPM 54 Cyclophosphamide 54 chronic ITP patients 54 MALT lymphoma 54 clinicopathologic 54 peripheral sensory neuropathy 53 KRAS wild 53 plus prednisone 53 NATRECOR ® 53 RhuDex R 53 Hepatocellular Carcinoma HCC 53 pancreatic ovarian 53 Tacrolimus 53 Dapagliflozin 53 peritoneal cancer 53 metastatic ovarian cancer 53 tibolone 53 Prospective Randomized 53 premalignant 53 YONDELIS 53 metastatic melanoma 53 femoral neck fracture 53 NYHA Class II 53 EOquin 53 B7 H3 53 neoplasm 53 Randomized Phase II 53 nodular 53 postmenopausal osteoporotic women 53 forodesine 53 sclerosing 53 non resectable 53 Androxal TM 53 Folfox 53 relapsed refractory 53 Camptosar ® 53 Myocardial Infarction 53 Phase #/#a trial 53 cetuximab Erbitux R 53 Epratuzumab 53 Metastases 53 K ras 53 breast carcinomas 53 nimotuzumab 53 osteogenic 53 Paraplatin ® carboplatin 53 corticosteroid therapy 53 mucinous 53 invasive candidiasis 53 everolimus eluting stents 53 Cholangiocarcinoma 53 malignancies 53 Peginterferon 53 adjuvant chemotherapy 53 tumoral 53 BRCA deficient 53 Dabigatran 53 irinotecan doxorubicin oxaliplatin paclitaxel 53 ASCT 53 5 FU leucovorin 53 ipsilateral breast 53 Platinol ® 53 ovarian breast 53 resection 53 HER2 positive cancers 53 XELOX 53 KRAS mutation 53 Malignant Melanoma 53 interferon IFN 53 Diffuse Large B 53 anthracycline chemotherapy 53 Alpharadin 53 myelofibrosis polycythemia vera 53 advanced epithelial ovarian 53 pancreatic NET 53 acute leukemias 53 Chronic Hepatitis C 53 Naive Patients 53 recombinant erythropoietin 53 small lymphocytic lymphoma 53 multicentre randomized 53 percutaneous transluminal coronary angioplasty 53 calcineurin inhibitors 53 CA4P 53 LEP ETU 53 anti leukemic 53 Fluorouracil 53 oncology indications 53 Squamous Cell Carcinoma 53 gastrointestinal stromal tumor GIST 53 sorafenib 53 HDAC Inhibitor 53 Dacogen injection 53 tumor xenograft models 53 previously untreated follicular 53 ibandronate 53 radiation sensitizer 53 mildly symptomatic 53 5 Fluorouracil 53 carotid artery stenting 53 ara C 53 Pegylated Interferon 53 allogeneic bone marrow 53 prognostic variables 53 HCV SPRINT 53 bendamustine 53 minimally symptomatic 53 antiangiogenic agent 53 Pharmacokinetics PK 53 RECIST Response Evaluation Criteria 53 p# biomarker 53 esophageal cancers 53 Enzyme Replacement Therapy 53 myeloablative 53 Halaven 53 T2DM 53 AEG# 53 lesional 53 cirrhotic 53 Localized Prostate Cancer 53 adenomatous polyps 53 VFEND 53 Epirubicin 53 castration resistant prostate cancer 53 Embolization 53 #F FDG PET 53 postoperative radiotherapy 53 oral ridaforolimus 53 Occlusive Disease 53 darinaparsin ZIO 53 Monotherapy 53 Gliadel Wafer 53 obese postmenopausal 53 HeFH 53 mycophenolate mofetil MMF 53 proteasome inhibitor 53 mCRC 53 palliation 53 mapatumumab 53 Imprime PGG 53 CMV disease 53 CEQ# 53 pretransplant 53 PROVENGE sipuleucel T 53 R vitespen 53 Crohn disease CD 53 Afatinib 53 eptifibatide 53 idarubicin 53 gastric cancer 53 pleural mesothelioma 53 incisional 53 Hycamtin ® 53 anthracycline containing 53 ICD implantation 53 Phase III Clinical Trial 53 PEGylated Fab fragment 53 paclitaxel cisplatin 53 trastuzumab 53 phase IIb trial 53 ARCOXIA 53 deferiprone 53 Renal Artery 53 Fludara ® 53 cutaneous melanoma 53 milatuzumab 53 mixed hyperlipidemia 53 Heart Failure Patients 53 metastatic adenocarcinoma 53 refractory colorectal cancer 53 xenograft 53 nodular BCC 53 octreotide 53 non metastatic osteosarcoma 53 grade glioma 53 fluvastatin 53 Eculizumab 53 Placebo Controlled Trial 53 pathologic fractures 53 olaparib 53 lymphoid malignancies 53 metastatic HER2 positive 53 immunomodulatory agents 53 invasive carcinoma 53 chemotherapy regimens 53 multicenter Phase II 53 carcinoid 53 small molecule tyrosine 53 NovoTTF 53 antithrombotic therapy 53 Cloretazine